Management of Alzheimer's Dementia

Medication Dosage and Administration

• The American Academy of Family Physicians recommends an initial dose of 1.5 mg twice daily (3 mg/day) for memantine, with titration increased by 1.5 mg twice daily (3 mg/day) every 4 weeks as tolerated, and a maximum dose of 6 mg twice daily (12 mg/day) 1
• The American Academy of Family Physicians suggests taking memantine with food to reduce gastrointestinal side effects 1
• For rivastigmine, the initial dose is 4 mg twice daily (8 mg/day) with morning and evening meals, with titration to 8 mg twice daily (16 mg/day) for at least 4 weeks, and a maximum dose of 12 mg twice daily (24 mg/day) based on individual response and tolerability 1
• Donepezil is recommended at a dosage of 5-10 mg daily, starting with 5 mg daily for 4-6 weeks and increasing to 10 mg daily if well tolerated, providing additional cognitive benefits 2
• Memantine is recommended at a dosage of 20 mg daily, titrated gradually, showing statistically significant improvement in cognition for moderate to severe Alzheimer's disease 3

Assessment and Monitoring

• Beneficial response to cholinesterase inhibitors should be determined from physician's global assessment, primary caregiver's report, neuropsychological assessment or mental status questionnaire, and evidence of behavioral or functional changes, as recommended by the American Academy of Family Physicians 1
• Observation for 6-12 months is usually necessary to assess potential benefit, according to the American Academy of Family Physicians 1
• Cholinesterase inhibitors should be discontinued if side effects develop and do not resolve, adherence is poor, or deterioration continues at the pretreatment rate after 6-12 months, as suggested by the American Academy of Family Physicians 1
• Regular assessment of cognitive function using appropriate tools like MMSE, MoCA, or condition-specific measures is recommended when using donepezil 4

Medication Selection and Switching

• Patients who do not respond to one cholinesterase inhibitor may respond to another, as noted by the American Academy of Family Physicians 1
• Tacrine is considered a second-line agent due to hepatotoxicity (occurring in 40% of treated patients) and the need for four-times-daily dosing, according to the American Academy of Family Physicians 1
• The American College of Physicians recommends using donepezil as the first-line treatment for mild to moderate dementia, while memantine is preferred for moderate to severe disease, with combination therapy offering the greatest benefit for moderate to severe Alzheimer's disease 2
• The combination of donepezil and memantine provides greater improvement than donepezil alone, with benefits including enhanced cognitive function, improved behavioral symptoms, and better global function 2, 3

Side Effects and Tolerability

• Taking medication with food can reduce gastrointestinal side effects, as recommended by the American Academy of Family Physicians 1
• Both medications are generally well-tolerated, with common side effects including nausea, diarrhea, anorexia, vomiting, dizziness, headache, confusion, and constipation 2, 3
• Donepezil is generally well-tolerated with most events being mild and transient, primarily gastrointestinal side effects, and no evidence of hepatotoxicity 2
• Memantine is generally better tolerated than cholinesterase inhibitors, with side effects including dizziness, headache, confusion, and constipation, and withdrawal rates due to adverse events similar to placebo 3

Efficacy and Benefits

• Donepezil demonstrates statistically significant improvements in cognition (2-3 points on ADAS-cog) and shows clinically significant improvements in global function assessment 2
• Memantine shows significant improvements in cognition, global function, and behavior, and is particularly beneficial for quality of life, caregiver burden, and resource utilization 2, 3
• Benefits of both medications are modest, and managing expectations with patients and caregivers is essential, with regular assessment of cognitive function necessary to monitor response 3
• Common pitfalls in patient management include expecting dramatic improvements, discontinuing treatment too early, overlooking combination therapy, and neglecting side effect management 3

Medication Comparison

Special Considerations

• Donepezil has been investigated for Parkinson's Disease Dementia, with some studies showing cognitive improvements in patients with Parkinson's disease dementia 2
• Donepezil has been investigated for Mild Cognitive Impairment, with mixed evidence showing short-term benefits in delaying conversion to Alzheimer's disease, but differences disappearing by 36 months 2
• Most studies on donepezil are relatively short-term (6 months or less), limiting conclusions about long-term efficacy 2